Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Severe Aortic Stenosis Due to a Unicommissural Unicuspid Aortic Valve with Commissural Intraleaflet Hemorrhage and Inflammation.

Internal medicine (Tokyo, Japan)·2026

Same author

Risk stratification and determinants of cardiac recovery in hemodialysis patients with reduced ejection fraction.

Heart and vessels·2026

Same author

Frequency synchronization facilitated by frequency differences: Dynamics of coupled-oscillator systems with damaged elements.

Chaos (Woodbury, N.Y.)·2026

Same author

Aortic Regurgitation Jet Increases Left Ventricular Energy Loss Associated With the Progression of Cardiac Failure　- A Vector Flow Mapping Analysis Study.

Circulation journal : official journal of the Japanese Circulation Society·2025

Same author

Infective Endocarditis Complicated by Ventricular Septal Defect and Coarctation of the Aorta, Suspected on Auscultation and Phonocardiography.

Internal medicine (Tokyo, Japan)·2025

Same author

Safety and therapeutic potential of allogeneic adipose-derived stem cell spray transplantation in ischemic cardiomyopathy: a phase I clinical trial.

Journal of translational medicine·2024

Search research articles

Related Experiment Video

Updated: May 8, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

[Heart transplantation and ventricular assit systems].

Takeshi Nakatani¹, Hiroki Hata, Tomoyuki Fujita

¹Department of Transplantation, National Cerebral and Cardiovascular Center Hospital, Suita, Japan.

Kyobu Geka. the Japanese Journal of Thoracic Surgery

|August 30, 2013

Summary

The National Cerebral and Cardiovascular Center has performed 50 heart transplants, achieving a 93.4% 10-year survival rate. Implantable left ventricular assist systems (LVAS) are now the preferred bridge to transplantation option.

More Related Videos

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: May 8, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

Cardiovascular Surgery
Transplantation Medicine
Medical Engineering

Context:

The organ transplantation law facilitated 50 heart transplants at the National Cerebral and Cardiovascular Center.
Initial treatments involved extracorporeal left ventricular assist systems (LVAS).
The center has a history of 139 LVAS applications.

Purpose:

To report outcomes of heart transplantation and the evolving role of left ventricular assist systems (LVAS).
To highlight the shift towards implantable LVAS as a primary bridge to transplantation strategy.

Summary:

50 heart transplants performed with a 93.4% 10-year survival rate.
Transition from extracorporeal to implantable LVAS for bridge to transplantation (BTT).
Two patients demonstrate long-term survival (>10 years) post-transplant.

Impact:

Implantable LVAS are now the preferred BTT strategy, improving patient selection and outcomes.
Demonstrates successful long-term outcomes in heart transplantation.
Establishes a benchmark for LVAS utilization in heart failure management.